346 related articles for article (PubMed ID: 36542856)
1. Radiotherapy-Triggered Proteolysis Targeting Chimera Prodrug Activation in Tumors.
Yang C; Yang Y; Li Y; Ni Q; Li J
J Am Chem Soc; 2023 Jan; 145(1):385-391. PubMed ID: 36542856
[TBL] [Abstract][Full Text] [Related]
2. Rational Design of Bioorthogonally Activatable PROTAC for Tumor-Targeted Protein Degradation.
Bi T; Liang P; Zhou Y; Wang H; Huang R; Sun Q; Shen H; Yang S; Ren W; Liu Z
J Med Chem; 2023 Nov; 66(21):14843-14852. PubMed ID: 37871321
[TBL] [Abstract][Full Text] [Related]
3. In situ albumin-binding and esterase-specifically cleaved BRD4-degrading PROTAC for targeted cancer therapy.
Cho H; Jeon SI; Shim MK; Ahn CH; Kim K
Biomaterials; 2023 Apr; 295():122038. PubMed ID: 36787659
[TBL] [Abstract][Full Text] [Related]
4. Radiation responsive PROTAC nanoparticles for tumor-specific proteolysis enhanced radiotherapy.
Xu M; Yun Y; Li C; Ruan Y; Muraoka O; Xie W; Sun X
J Mater Chem B; 2024 Mar; 12(13):3240-3248. PubMed ID: 38437473
[TBL] [Abstract][Full Text] [Related]
5. Targeted delivery of PROTAC-based prodrug activated by bond-cleavage bioorthogonal chemistry for microneedle-assisted cancer therapy.
Huang J; Yao Z; Li B; Ping Y
J Control Release; 2023 Sep; 361():270-279. PubMed ID: 37541594
[TBL] [Abstract][Full Text] [Related]
6. Near-Infrared-Activatable PROTAC Nanocages for Controllable Target Protein Degradation and On-Demand Antitumor Therapy.
He Q; Zhou L; Yu D; Zhu R; Chen Y; Song M; Liu X; Liao Y; Ding T; Fan W; Yu W
J Med Chem; 2023 Aug; 66(15):10458-10472. PubMed ID: 37279091
[TBL] [Abstract][Full Text] [Related]
7. Engineered bioorthogonal POLY-PROTAC nanoparticles for tumour-specific protein degradation and precise cancer therapy.
Gao J; Hou B; Zhu Q; Yang L; Jiang X; Zou Z; Li X; Xu T; Zheng M; Chen YH; Xu Z; Xu H; Yu H
Nat Commun; 2022 Jul; 13(1):4318. PubMed ID: 35882867
[TBL] [Abstract][Full Text] [Related]
8. PROTAC Prodrug-Integrated Nanosensitizer for Potentiating Radiation Therapy of Cancer.
Zhang S; Lai Y; Pan J; Saeed M; Li S; Zhou H; Jiang X; Gao J; Zhu Y; Yu H; Zhang W; Xu Z
Adv Mater; 2024 Jun; 36(23):e2314132. PubMed ID: 38353332
[TBL] [Abstract][Full Text] [Related]
9. Bridged Proteolysis Targeting Chimera (PROTAC) Enables Degradation of Undruggable Targets.
Xiong Y; Zhong Y; Yim H; Yang X; Park KS; Xie L; Poulikakos PI; Han X; Xiong Y; Chen X; Liu J; Jin J
J Am Chem Soc; 2022 Dec; 144(49):22622-22632. PubMed ID: 36448571
[TBL] [Abstract][Full Text] [Related]
10. Recent Advances in Pro-PROTAC Development to Address On-Target Off-Tumor Toxicity.
Chen C; Yang Y; Wang Z; Li H; Dong C; Zhang X
J Med Chem; 2023 Jul; 66(13):8428-8440. PubMed ID: 37317568
[TBL] [Abstract][Full Text] [Related]
11. [Advances in targeted delivery of proteolysis targeting chimeras in cancer therapy].
Wu X; Zhao J; Gao Y; Yao Q; Xie J
Sheng Wu Gong Cheng Xue Bao; 2023 Sep; 39(9):3628-3643. PubMed ID: 37805843
[TBL] [Abstract][Full Text] [Related]
12. Selective degradation of BRD4 suppresses lung cancer cell proliferation using GSH-responsive PROTAC precursors.
Fan H; Zhou Z; Yu D; Sun J; Wang L; Jia Y; Tian J; Mi W; Sun H
Bioorg Chem; 2023 Nov; 140():106793. PubMed ID: 37683536
[TBL] [Abstract][Full Text] [Related]
13. Enhanced Tumor Targeting and Penetration of Proteolysis-Targeting Chimeras through iRGD Peptide Conjugation: A Strategy for Precise Protein Degradation in Breast Cancer.
He S; Fang Y; Wu M; Zhang P; Gao F; Hu H; Sheng C; Dong G
J Med Chem; 2023 Dec; 66(24):16828-16842. PubMed ID: 38055861
[TBL] [Abstract][Full Text] [Related]
14. Photo-regulated PROTACs: A novel tool for temporal control of targeted protein degradation.
Xu H; Ohoka N; Inoue T; Yokoo H; Demizu Y
Bioorg Med Chem Lett; 2024 Jul; 107():129778. PubMed ID: 38702019
[TBL] [Abstract][Full Text] [Related]
15. Stimuli-activatable PROTACs for precise protein degradation and cancer therapy.
Gao J; Yang L; Lei S; Zhou F; Nie H; Peng B; Xu T; Chen X; Yang X; Sheng C; Rao Y; Pu K; Jin J; Xu Z; Yu H
Sci Bull (Beijing); 2023 May; 68(10):1069-1085. PubMed ID: 37169612
[TBL] [Abstract][Full Text] [Related]
16. Aptamer-PROTAC Conjugates (APCs) for Tumor-Specific Targeting in Breast Cancer.
He S; Gao F; Ma J; Ma H; Dong G; Sheng C
Angew Chem Int Ed Engl; 2021 Oct; 60(43):23299-23305. PubMed ID: 34240523
[TBL] [Abstract][Full Text] [Related]
17. Antibody-PROTAC Conjugates Enable HER2-Dependent Targeted Protein Degradation of BRD4.
Maneiro MA; Forte N; Shchepinova MM; Kounde CS; Chudasama V; Baker JR; Tate EW
ACS Chem Biol; 2020 Jun; 15(6):1306-1312. PubMed ID: 32338867
[TBL] [Abstract][Full Text] [Related]
18. Nanoformulation of BRD4-Degrading PROTAC: Improving Druggability To Target the 'Undruggable' MYC in Pancreatic Cancer.
Minko T
Trends Pharmacol Sci; 2020 Oct; 41(10):684-686. PubMed ID: 32893006
[TBL] [Abstract][Full Text] [Related]
19. PROTAC-biomacromolecule conjugates for precise protein degradation in cancer therapy: A review.
Wang C; Zhang Y; Yu W; Xu J; Xing D
Int J Biol Macromol; 2024 Mar; 261(Pt 2):129864. PubMed ID: 38302015
[TBL] [Abstract][Full Text] [Related]
20. Tumor-targeted PROTAC prodrug nanoplatform enables precise protein degradation and combination cancer therapy.
Zou ZF; Yang L; Nie HJ; Gao J; Lei SM; Lai Y; Zhang F; Wagner E; Yu HJ; Chen XH; Xu ZA
Acta Pharmacol Sin; 2024 Apr; ():. PubMed ID: 38609561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
